Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GNMSF) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to $5.2 billion.

  • Genmab A's Cash from Financing Activities rose 102385.16% to $5.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $4.8 billion, marking a year-over-year increase of 52305.65%. This contributed to the annual value of $4.8 billion for FY2025, which is 94611.31% up from last year.
  • Latest data reveals that Genmab A reported Cash from Financing Activities of $5.2 billion as of Q4 2025, which was up 102385.16% from -$21.0 million recorded in Q3 2025.
  • Over the past 5 years, Genmab A's Cash from Financing Activities peaked at $5.2 billion during Q4 2025, and registered a low of -$566.0 million during Q4 2024.
  • For the 3-year period, Genmab A's Cash from Financing Activities averaged around $396.4 million, with its median value being -$85.0 million (2024).
  • As far as peak fluctuations go, Genmab A's Cash from Financing Activities plummeted by 53595.51% in 2024, and later skyrocketed by 102385.16% in 2025.
  • Genmab A's Cash from Financing Activities (Quarter) stood at -$89.0 million in 2023, then crashed by 535.96% to -$566.0 million in 2024, then surged by 1023.85% to $5.2 billion in 2025.
  • Its Cash from Financing Activities stands at $5.2 billion for Q4 2025, versus -$21.0 million for Q3 2025 and -$406.0 million for Q2 2025.